Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT02687932
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 118 participants
- Sponsor
- Registry
-
NCT02687932
-
- Other papers using this trial's data
- Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02687932. Randomized; quadruple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2018-01-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
- Acronym
- PRIME
- Condition
- Mitral Valve Insufficiency
- Condition
- Left Ventricular Dysfunction
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Asan Medical Center
- Collaborator
- Novartis
Record details
- Record id
cardio:ct-nct02687932- Content hash
a9788c90ea8b19224d791129ba6a8af48330afca55d996048be8ecb1ff3418e3